RA
AVNS

Royce & Associates’s Avanos Medical AVNS Stock Holding History

Royce & Associates’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Sell
60,703
-453,000
-88% -$10.6M 0.01% 646
2026
Q1 		$7.2M Buy
513,703
+453,000
+746% +$6.1M 0.07% 406
2025
Q4 		$682K Buy
60,703
+28,482
+88% +$326K 0.01% 685
2025
Q3 		$372K Buy
+32,221
New +$377K ﹤0.01% 723
2015
Q4 		– Sell
-84,500
Closed -$2.4M – 1122
2015
Q3 		$2.4M Buy
+84,500
New +$2.95M 0.01% 828

Other funds holding AVNS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Royce & Associates's AVNS Position: Q2 2026 in Review

Royce & Associates reduced its Avanos Medical (AVNS) stake by 88% in Q2 2026, selling an estimated $10.6M and leaving 60,703 shares worth $1.51M. The position accounts for 0.01% of the portfolio, ranked #646.

Royce & Associates first reported a position in AVNS in Q3 2015 and has held it in 5 quarters since. The position peaked at $7.2M in Q1 2026. 286 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

  • Royce & Associates held 60,703 shares of Avanos Medical worth $1.51M as of Q2 2026.
  • Royce & Associates sold 453,000 Avanos Medical shares in Q2 2026, an estimated $10.6M.
  • Avanos Medical made up 0.01% of Royce & Associates's portfolio in Q2 2026, its #646 holding.
  • Royce & Associates first reported a position in Avanos Medical in Q3 2015 and has held it in 5 quarters since.
  • Royce & Associates's Avanos Medical position peaked at $7.2M in Q1 2026.
  • 286 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.